Martin Shkreli Predicts 90% Drop in Inmune Bio Stock

Summary

Former hedge fund manager Martin Shkreli predicts that the stock of Inmune Bio Inc. could fall by 90%, potentially dropping from its closing price of $5.33 to $0.50 by Monday. This warning comes after the stock recently surged due to investor enthusiasm for its neuroinflammation candidate drug. Shkreli criticizes the company for lacking robust trial data and peer-reviewed publications. His claims are supported by activist short seller BMF Reports, which raised concerns about the company’s science and trial design. Inmune Bio’s stock fell by 15.13% on Friday and an additional 16.32% after hours.Benzinga

Impact Analysis

This event is primarily at the company level, as it concerns Inmune Bio Inc. and its stock performance. However, there is also a significant influence from public figures, as Martin Shkreli’s prediction and BMF Reports’ support have notably impacted investor sentiment.

Inference Graphs Analysis:

• Information Node (Top Level):
• Martin Shkreli’s prediction about Inmune Bio’s stock decline.
• Concerns from BMF Reports regarding scientific and trial design credibility.
• First-Order Effects:
• Immediate stock price drop (15.13% during trading hours and 16.32% after hours).
• Investor uncertainty and potential panic selling due to the perceived lack of strong scientific backing.
• Second-Order Effects:
• Potential broader skepticism towards similar biotech firms lacking solid trial data.
• Possible increased scrutiny or regulatory focus on biotech trials and data publication.
• Investment Opportunities/Risks:
• Short selling opportunities on Inmune Bio if the prediction proves accurate.
• Risks involved in holding or purchasing Inmune Bio shares given the current volatility and criticism.
• Potential to explore other biotech stocks with robust trial data to capitalize on the sector’s volatility.Benzinga